Literature DB >> 11761725

Perisomatic granules (non-plaque dystrophic dendrites) of hippocampal CA1 neurons in Alzheimer's disease and Pick's disease: a lesion distinct from granulovacuolar degeneration.

A Probst1, M C Herzig, C Mistl, S Ipsen, M Tolnay.   

Abstract

A number of pathological changes have been reported in relation to CA1 pyramidal cells in Alzheimer's disease (AD), among them hyperphosphorylation of tau protein followed by the formation of filamentous tau lesions, granulovacuolar degeneration (GVD), Hirano bodies and spindle-shaped dilatations of distal apical dendrites. Juxtacellular clusters of glutamate receptor (GluR)-positive granules around pyramidal cells of the CA1 sector have been recently reported under the term "non-plaque dystrophic dendrites". We independently found that CA1 pyramidal cells in AD patients are regularly surrounded by ubiquitin-positive granules measuring 1-4 microns in diameter, which we have termed perisomatic granules (PSG). Using confocal microscopy, ubiquitin- and GluR-reactive granules were found to largely coincide and to correspond to the same structure. By immunoelectron microscopy PSG were found to consist of GluR1-2-reactive enlarged synaptic boutons containing tubulo-filamentous or floccular material. PSG were found to be consistently associated with pyramidal (principal) cells but not with interneurons of the CA1 sector. Dual-labeling experiments have shown that PSG are preferentially associated with tau-immunoreactive "pretangle" neurons but not with cells containing filamentous tau inclusions or with tau-negative nerve cell bodies. The number of PSG was found to increase with the severity of AD changes with almost no PSG found in Braak stages I and II and few in stage III. Furthermore, PSG were not AD specific, as shown by their presence around CA1 pyramidal cells in Pick's disease. The reasons for GluR reactivity and ubiquitin complex formation in enlarged perisomatic boutons are unclear. Marked changes in GluR subunits have been observed in association with even moderate AD pathology in hippocampal pyramidal cells in AD and our findings suggest a pathogenic link between PSG and early tau pathology in CA1 neurons. PSG might represent residual and abnormally clustered GluR subunits in degenerating perisomatic neurites. Our work confirms and extend previous study on perisomatic "non-plaque dystrophic dendrites" in AD and establish PSG as a pathological entity distinct from GVD. In addition PSG should be acknowledged among main histological changes associated with hippocampal neurons in AD and Pick's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761725     DOI: 10.1007/s004010100420

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

1.  The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus.

Authors:  Jeroen J M Hoozemans; Elise S van Haastert; Diana A T Nijholt; Annemieke J M Rozemuller; Piet Eikelenboom; Wiep Scheper
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

Review 2.  Axonal degeneration as a therapeutic target in the CNS.

Authors:  Paul Lingor; Jan C Koch; Lars Tönges; Mathias Bähr
Journal:  Cell Tissue Res       Date:  2012-03-06       Impact factor: 5.249

3.  At the centre of neuronal, synaptic and axonal pathology in murine prion disease: degeneration of neuroanatomically linked thalamic and brainstem nuclei.

Authors:  Renata Reis; Edel Hennessy; Caoimhe Murray; Éadaoin W Griffin; Colm Cunningham
Journal:  Neuropathol Appl Neurobiol       Date:  2015-05-30       Impact factor: 8.090

Review 4.  Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies.

Authors:  Vera I Wiersma; Jeroen J M Hoozemans; Wiep Scheper
Journal:  Acta Neuropathol Commun       Date:  2020-09-03       Impact factor: 7.801

5.  Ubiquilin 2 is not associated with tau pathology.

Authors:  Anna Nölle; Elise S van Haastert; Rob Zwart; Jeroen J M Hoozemans; Wiep Scheper
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.